[1] Gritsch, S.; Batchelor, T.T.; Gonzalez Castro, L.N., Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer, 2022, 128, (1), 47-58.
[2] Alzoubi, H.; Alsabbah, A.; Caltabiano, R.; Broggi, G., The Integrated Histopathologic and Molecular Approach to Adult-type Diffuse Astrocytomas: Status of the Art, Based on the 2021 WHO Classification of Central Nervous System Tumors. Oncologie, 2022, 24, (1), 51--63.
[3] Lapointe, S.; Perry, A.; Butowski, N.A., Primary brain tumours in adults. Lancet (London, England), 2018, 392, (10145), 432-446.
[4] Kurdi, M.; Fadul, M.M.; Addas, B.; Faizo, E.; Bamaga, A.K.; Alsinani, T.; Katib, Y.; Alkhotani, A.; Fathaddin, A.A.; Turkistani, A.N.; Najjar, A.A.; Baeesa, S.; Toonsi, F.A.; Almansouri, M.; Alkhayyat, S., Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression. Oncologie, 2024.
[5] Yasinjan, F.; Xing, Y.; Geng, H.; Guo, R.; Yang, L.; Liu, Z.; Wang, H., Immunotherapy: a promising approach for glioma treatment. Frontiers in immunology, 2023, 14, 1255611.
[6] Sareen, H.; Ma, Y.; Becker, T.M.; Roberts, T.L.; de Souza, P.; Powter, B., Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. International journal of molecular sciences, 2022, 23, (16).
[7] Gu, X.-Y.; Huo, J.-L.; Yu, Z.-Y.; Jiang, J.-C.; Xu, Y.-X.; Zhao, L.-J., Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. Oncologie, 2024, 26, (1), 9-25.
[8] Kroemer, G.; Galassi, C.; Zitvogel, L.; Galluzzi, L., Immunogenic cell stress and death. Nature immunology, 2022, 23, (4), 487-500.
[9] Ahmed, A.; Tait, S.W.G., Targeting immunogenic cell death in cancer. Molecular oncology, 2020, 14, (12), 2994-3006.
[10] Fucikova, J.; Kepp, O.; Kasikova, L.; Petroni, G.; Yamazaki, T.; Liu, P.; Zhao, L.; Spisek, R.; Kroemer, G.; Galluzzi, L., Detection of immunogenic cell death and its relevance for cancer therapy. Cell death & disease, 2020, 11, (11), 1013.
[11] Valančiūtė, A.; Mathieson, L.; O'Connor, R.A.; Scott, J.I.; Vendrell, M.; Dorward, D.A.; Akram, A.R.; Dhaliwal, K., Phototherapeutic Induction of Immunogenic Cell Death and CD8+ T Cell-Granzyme B Mediated Cytolysis in Human Lung Cancer Cells and Organoids. Cancers, 2022, 14, (17).
[12] Ruan, H.; Leibowitz, B.J.; Zhang, L.; Yu, J., Immunogenic cell death in colon cancer prevention and therapy. Molecular carcinogenesis, 2020, 59, (7), 783-793.
[13] Tukaramrao, D.B.; Malla, S.; Saraiya, S.; Hanely, R.A.; Ray, A.; Kumari, S.; Raman, D.; Tiwari, A.K., A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells. Cancers, 2021, 13, (8).
[14] Langfelder, P.; Horvath, S., WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics, 2008, 9, 559.
[15] Kassambara, A.; Kosinski, M.; Biecek, P.; Fabian, S., Package ‘survminer’. Drawing Survival Curves using ‘ggplot2’(R package version 03 1), 2017.
[16] Blanche, P.; Dartigues, J.F.; Jacqmin-Gadda, H., Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Statistics in medicine, 2013, 32, (30), 5381-5397.
[17] Mayakonda, A.; Lin, D.C.; Assenov, Y.; Plass, C.; Koeffler, H.P., Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome research, 2018, 28, (11), 1747-1756.
[18] Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y., clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology, 2012, 16, (5), 284-287.
[19] Charoentong, P.; Finotello, F.; Angelova, M.; Mayer, C.; Efremova, M.; Rieder, D.; Hackl, H.; Trajanoski, Z., Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell reports, 2017, 18, (1), 248-262.
[20] Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research, 2003, 13, (11), 2498-2504.
[21] Garg, A.D.; De Ruysscher, D.; Agostinis, P., Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. Oncoimmunology, 2016, 5, (2), e1069938.
[22] Rong, L.; Li, N.; Zhang, Z., Emerging therapies for glioblastoma: current state and future directions. Journal of experimental & clinical cancer research : CR, 2022, 41, (1), 142.
[23] Li, Z.; Lai, X.; Fu, S.; Ren, L.; Cai, H.; Zhang, H.; Gu, Z.; Ma, X.; Luo, K., Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, 9, (22), e2201734.
[24] Galluzzi, L.; Kepp, O.; Hett, E.; Kroemer, G.; Marincola, F.M., Immunogenic cell death in cancer: concept and therapeutic implications. Journal of translational medicine, 2023, 21, (1), 162.
[25] Diesel, B.; Radermacher, J.; Bureik, M.; Bernhardt, R.; Seifert, M.; Reichrath, J.; Fischer, U.; Meese, E., Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, 11, (15), 5370-5380.
[26] Qu, M.; Di, S.; Zhang, S.; Xia, Z.; Quan, G., Vitamin D receptor protects glioblastoma A172 cells against Coxsackievirus A16 infection induced cell death in the pathogenesis of hand, foot, and mouth disease. Biochemical and biophysical research communications, 2017, 493, (2), 952-956.
[27] Salomón, D.G.; Fermento, M.E.; Gandini, N.A.; Ferronato, M.J.; Arévalo, J.; Blasco, J.; Andrés, N.C.; Zenklusen, J.C.; Curino, A.C.; Facchinetti, M.M., Vitamin D receptor expression is associated with improved overall survival in human glioblastoma multiforme. Journal of neuro-oncology, 2014, 118, (1), 49-60.
[28] Srivastava, S.; Makala, H.; Sharma, V.; Suri, V.; Sarkar, C.; Kulshreshtha, R.J.C.; CMLS, m.l.s., MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis. 2022, 79, (2), 104.
[29] Wang, Z.; Mo, Y.; Tan, Y.; Wen, Z.; Dai, Z.; Zhang, H.; Zhang, X.; Feng, S.; Liang, X.; Song, T.; Cheng, Q.J.F.i.i., The ALDH Family Contributes to Immunocyte Infiltration, Proliferation and Epithelial-Mesenchymal Transformation in Glioma. 2021, 12, 756606.
[30] Ho, K.; Cheng, C.; Chou, C.; Chen, P.; Liu, A.; Lin, C.; Shih, C.; Chen, K.J.P.r., miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. 2019, 147, 104390.
[31] Wu, P.; Guo, Y.; Xiao, L.; Yuan, J.; Tang, C.; Dong, J.; Qian, Z.J.C.i., immunotherapy : CII, LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells. 2023.
[32] Tiwari, S.; Siddiqi, S.; Siddiqi, S.J.T.J.o.b.c., CideB protein is required for the biogenesis of very low density lipoprotein (VLDL) transport vesicle. 2013, 288, (7), 5157-5165.
[33] Virassamy, B.; Caramia, F.; Savas, P.; Sant, S.; Wang, J.; Christo, S.N.; Byrne, A.; Clarke, K.; Brown, E.; Teo, Z.L.; von Scheidt, B.; Freestone, D.; Gandolfo, L.C.; Weber, K.; Teply-Szymanski, J.; Li, R.; Luen, S.J.; Denkert, C.; Loibl, S.; Lucas, O.; Swanton, C.; Speed, T.P.; Darcy, P.K.; Neeson, P.J.; Mackay, L.K.; Loi, S., Intratumoral CD8(+) T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer. Cancer cell, 2023, 41, (3), 585-601.e588.
[34] Tay, C.; Tanaka, A.; Sakaguchi, S., Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer cell, 2023, 41, (3), 450-465.